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1. Introduction 
Every year 1.6 million of newborn infants die from sepsis (Lawn et al 2000). The prevalence 
of sepsis, meningitis, and other confirmed bacterial infections has been estimated to range 
between 1 to 5/1000 live births. Preterm infants are 20 times more likely to get infection than 
term infants with a prevalence of 1/230 (Haque KN 2003). Very low birth weight infants, 
evaluated and treated for infections are around 50% of all admissions to neonatal intensive 
care (Stoll et al 2003).  
Sepsis is responsible for 30–80% increased risk of neuro-developmental impairment and  
30–100% increase in odds for poor head growth and long term morbidity (Stoll et al 2004). 
45% of late deaths in the Neonatal Intensive Care Unit (NICU) are caused by an infectiouse 
disease (Ince 2005). Despite assistance progress, mortality rates from sepsis have not 
declined over the last three decades (Haque 2003).  
While the incidence of sepsis is known, the true incidence of septic shock in neonates has 
not been well documented. It is estimated to be around 1–5% of all infants with proven 
severe sepsis (Haque 2004). Kermorvant-Duchemin E. et al.(2008) reported septic shock in 
1.3% of extremely low birth weight newborns with an associated mortality peaking at 71%.  
2. Definition and risk factors 
Infection, far from being a homogeneous condition, reflects a continuum from fetal 
inflammatory response syndrome to sepsis, severe sepsis, septic shock, multiorgan failure, 
and death. The difficulty for the clinician is to define precisely the phase in which his/her 
patient is at any given moment as the patient may move from one phase to another 
imperceptibly (Haque 2007).  
Definition of sepsis derives from the international consensus definitions that have been 
adapted for pediatric and neonatal use, including term neonates (0-7 days) and newborns (1 
week to 1 month) (Carcillo et al 2002, Goldestein et al 2005) (tab 1 and 2). Sepsis is a complex 
entity, with wide variations in clinical, laboratory parameters and outcome. Septic shock is a 
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condition of inadequate tissue perfusion secondary to cardiovascular dysfunction occurring 
in the course of suspected or certain systemic infection, requiring fluid resuscitation or 
inotropic support (Goldstein et al 2005, Haque 2007). This definition, valid for newborns 
born > 37 weeks gestation, is problematic for preterms due to immaturity of organ systems 
and transitional physiology (Jones 2008). For these reasons, the hemodynamic response to 
septic shock and optimum clinical interventions in preterm neonates are not well 
understood.  
Risk factors for a neonate to develop septic shock have not been described in detail, but they 
overlap those for sepsis. Prenatal risk factors include maternal intrapartum fever, 
chorioamnionitis or prolonged rupture of membranes, treatment with steroids, group B 
Streptoccocci recto-vaginal colonization. A few days after aspiration of infected amniotic 
fluid during the birth, the neonate may manifest with signs and symptoms of neonatal 
shock. Gram-positive germs as group B Streptococci are those most frequently described as 
causative agents in early neonatal sepsis, even if, more recently, some gram-negative agents 
have been frequently described (Escherichia coli, Klebsiella spp., Enterobacter spp.). This 
probably is due to the intrapartum use of antibiotics directed against gram-positive 
pathogens that allows gram-negative flora’s outbreak (Schrag et al 2007). Other microbes 
include Listeria monocytogenes, coagulase-negative staphylococci (ConS) (22%) and nonpyogenic 
streptococci (9%) (Muller-Pebody et al. 2011).  
Post-natal risk factors include: male gender, birth weight less than 1000 g, 
hypogammaglobulinemia, parenteral nutrition, central venous catheters, steroids or drugs 
that decrease gastric acidity, prolonged duration of mechanical ventilation, hand 
contamination of health care personnel, mother and other family members, aspiration of 
feeds, and disruption of skin integrity. Staphylococcus aureus is the most frequent germ in late 
sepsis. Gram negative and ConS, almost half the isolates (45%), are the predominant 
pathogens associated with late severe sepsis or septic shock ((Muller-Pebody et al. 2011).). 
Also viruses (herpes simplex, enteroviruses) or fungi (candida albicans) have been associated 
with fulminant neonatal sepsis. Compared with ConS, Gram-negative infections are 
associated with a higher mortality: one-fifth of those infected by gram negatives die. (Stoll et 
al 2002, Gordon et al 2006).  
3. Pathophysiology  
The development of septic shock is associated with elevated levels of proinflammatory 
cytokines including IL-1ǃ, IL-6, IL-8 and TNFǂ (Lynch et al 2008). The inflammatory 
cytokine response to sepsis in neonates is more pronounced and faster than in adults and 
associated with an increase in early mortality (<48 hours), while the compensatory anti-
inflammatory response system appears to be immature, with both term and preterm infants 
demonstrating profoundly decreased IL-10 production and a lower amount of transforming 
growth factor beta-positive lymphocytes, than do adults, after lipopolysaccharide (LPS) 
stimulation (Langer et al 2006). In addition, in the neonate eosinophils, macrophages and 
polymorphonuclear neutrophils have reduced surface binding components and have 
defective opsonization, phagocytosis and antigen-processing capabilities, leading to a 
generally less robust response to pathogen exposure (Urlichs et al 2006, Marodi et al 2006). 
Several studies indicate that the mechanisms of sepsis include excessive activation of the 
coagulation cascade, inhibition of endogenous natural anticoagulants, and impaired 
fibrinolysis (Short 2004). Within the microcirculation, this leads to fibrin deposition, 
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contributing to hypoperfusion that eventually results in tissue damage and organ 
dysfunction. On the other hand, consumption of coagulation factors and platelets promotes 
a bleeding tendency that may clinically manifest as petechiae, ecchymoses, and sometimes 
hemorrhages, all of which are associated to increased mortality. (Fourrier et al 1992, Kenet et 
l 2008, Levi 2010). The immune system and coagulation are closely related. Cytokines 
mediating neutrophils activation and migration to the tissues and extravascular 
compartment, generate the thrombin and fibrin deposit formation, triggering tissue factor, 
that is considered the main both septic shock and diffuse tissue injury mediator. That’s why, 
disseminated intravascular coagulation (DIC) is not so rare in septic shock, resulting from 
the sustained thrombin generation. Thrombin, in turn, stimulates more inflammatory 
mediators’ formation. Fibrin formation stabilizes platelet plugs, in addition to its important 
role in pathogens’ adhesion to the leukocyte surface, facilitating phagocytosis (Levi et 2010).  
The Toll-like receptors (TLRs), found in immune system cells, have a fundamental role in 
the septic shock pathophysiology. They can interfere with the cardiovascular system 
depending on the systemic inflammatory response to pathogen. They are able to detect 
pathogens-associated molecular patterns (PAMPs), causing the induction of pro-
inflammatory and anti-inflammatory mediators, particularly cytokines.(Gao et al 2008Gao et 
al 2005, Fleer et al 2007). TLRs, present in endothelial cells, alveolar epithelium cells, and 
cardiomyocytes, may induced TNFǂ and IL-1ǃ production, responsible for the early 
myocardial dysfunction in gram-negative (TLR4) and gram-positive (TLR2) germs severe 
sepsis.(Zhang et al 2007). Unlike in adults, TLRs genetic polymorphisms and signaling pro-
teins (MYD88) regulating the host response to infection and different septic shock patterns, 
are less characterized in neonates. (Zhang et al 2007, Cornell et al 2010).  
In septic shock the action of inflammatory mediators leads to damage of the capillary 
wall with loss of vascular tone, resulting in vasodilatation and reduction of systemic vascular 
resistance with low to normal blood pressure and increased systemic blood flow. Thanks to 
the compensatory heart rate increase, skin is well perfused and warm (warm shock). In the late 
phase of shock there is a reduction of myocardial contractility that leads to vasoconstriction, 
decreased systemic blood flow, decreased pulse volume, cold periphery, prolonged capillary 
refill time, and increased vascular tone in an attempt to centralize the circulation (cold shock). 
Shock, that is not recognized and treated, progresses from early to late stages, referred to as 
compensated, uncompensated, and irreversible shock. (Jones et al 2008).  
The hemodynamic response to sepsis of a newborn is markedly different from that of an 
adults or an older child with relevant difference between the preterm and the term newborn 
owing to the different anatomical structure, the functional activity and excitation–
contraction (Brierley et al 2008). 
In the neonates, the absence of hypotension does not precludes shock that is mainly related 
with blood flow rather than blood pressure as the mean blood pressure may be in the 
normal range due to compensatory mechanisms (Cayabyab et al 2009).  
In the evaluation of blood pressure, the physiological variability with age and gestational 
age should be taken in account (Silveira et al 2010). Despite this, 30 mmHg should be 
considered the absolute minimum tolerable of in the extremely premature infants. (Munro et 
al 2004). Furthermore in critically ill prematures, refractory hypotension may be related to 
patent ductus arteriosus, intraventricular hemorrhage and poor prognosis. (Carcillo et al 
2002). While in healthy prematures lower mean blood pressure levels may be accepted being 
associated with appropriate cerebral perfusion and normal cardiac output (30), in septic 
shock hypotension is not permissive and need a therapeutical intervent.  
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The neonate is enable to increase the stroke volume or myocardial contractility in case of 
sepsis, due to different physiologic abnormalities: a relatively decreased left ventricular 
muscle mass (Joyce et al 2004), an impaired left ventricular diastolic function and alterations 
in mid-wall left ventricular fractional shortening (Kozak-Barany et al 2001). These 
differences may be mediated by alterations in calcium channel expression and activity, in 
ATP-sensitive potassium channel function and in ǃ-receptor coupling (Huang et al 2006, 
Morrissey et al 2005).  
These developmental alterations make the neonates critically dependent on increasing the 
heart rate to generate increased cardiac output, but unable to compensate in this manner 
because of their relatively higher baseline heart rate (Carcillo et al 2009).  
The development of cardiovascular disfunction and septic shock make newborn infants 
susceptible to sudden cardiac deterioration, also because left ventricular sistolic 
performance is highly dependent on afterload. So the reopening of a patent ductus 
arteriosus and the development of persistent pulmonary hypertension (Carcillo et al 2002) 
may complicate the cardiovascular response to sepsis.  
4. Clinical features 
Septic shock should be suspected in any newborn with tachycardia, respiratory distress, 
poor feeding, poor tone, poor color, tachypnea, diarrhea or reduced perfusion particularly 
in the presence of prenatal risk factors like chorionamnionitis or prolonged rupture of 
membranes. (Kisson et al 2010) 
The predominant clinical sign is circulatory failure that can coexist with multiple organ 
damage, severe coagulopathy, metabolic acidosis and electrolyte alterations. During the 
compensated stage blood pressure remains normal and cardiac output is maintained. 
Clinical signs are pallor, increased capillary refill time (refill> 2’’), tachycardia, decreased 
urine output, mild agitation and confusion, signs of cerebral hypoperfusion. When 
compensatory mechanisms fail, cardiac output falls resulting in a reduction of oxygenation 
and increase of anaerobic metabolic mechanisms. The toe/core temperature gap widens, 
and the peripheries become cool and mottled, the pulse becomes small and weak, oliguria 
worsens to the point of anuria. The further deterioration of cerebral perfusion leads to 
irritability, sleepiness and impairment of conscious state. Despite intense peripheral 
vasoconstriction, hypotension occurs. In the meantime, the clinical condition of the newborn 
becomes critical. The lack of adequate resuscitation leads to a state of irreversible 
shock which causes the death of the baby. Furthermore, in newborn babies septic shock may 
be complicated by the physiological transition from fetal to neonatal circulation. Newborn 
septic shock is tipically accompanied by, acidosis and hypoxia that can lead to an increase in 
pulmonary resistance and persistence of the patent ductus Botallo, resulting in persistent 
fetal circulation which will result in right ventricle failure with right to left shunting at the 
atrial and ductus arteriosus levels causing cyanosis, hepatomegaly and tricuspid 
regurgitation. (Brierley et al 2009)  
5. Diagnosis 
Early recognition of neonatal shock allows to establish an adequate therapy and save lives 
(Han et al 2003). Ideally shock should be clinically diagnosed before hypotension occurs. 
Laboratory diagnosis is mainly based on controlling the blood gases, complete blood 
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count with differential, glucose, electrolytes, albumin, creatinine, urea, lactate, blood 
pyruvate, coagulationparameters, serum and urine osmolarity, cultures with susceptibility 
testing (blood culture, urine culture, culture catheters or drainage).  
Research offers an increasing number of biological markers for early detection of sepsis, but 
many of them failed to differentiate between sepsis and other non septic critical illness. The 
most commonly available and used markers are shown in table 3 (Haque 2005). 
Procalcitonine (PCT) revealed superior to C reactive protein (CRP) to differentiate children 
with sepsis from those with septic shock (Simon et al 2006), mainly at admission and 12 h 
later (Fioretto et al 2010). Baruti Garufi et al. (2010) found that the increase of PCT levels was 
related to the severity, course and prognosis of disease. Procalcitonin values were 
significantly increased in neonates with septic shock (92.5 ng/mL) compared to those with 
systemic inflammatory response syndrome- SIRS (41 ng/mL), neonatal sepsis (10,26 
ng/mL) and purulent meningitis (9,80 ng/mL). CRP was increased without statistical 
differences in all stages. Casado-Flores et al. (2006) observed a stronger correlation between 
PCT and PRISM score in septic shock than RCP, possibly due to the kinetics of this mediator 
that after an approximately 2 h latency period from initial stimulus, rises to a plateau within 
12–48 h and then slowly declines.  
Serum lactate level is considered an important biomarker to distinguish sepsis from septic 
shock. Normally a small amount of lactate is produced and all healthy tissue have the 
capacity to convert it, in aerobic condition, to pyruvate, used for cellular metabolism. When 
sepsis-associated multisystem organ failure occurs, this metabolic capacity, in anaerobic 
condition, is decreased and lactate levels rise. In the past the lactate levels were used to 
distinguish between state of adeguate perfusion and poor oxygen delivery. At present, as 
has been that lactate could be increased by others factors like adrenergic stimuli and lung 
injury, it became important to consider the increase lactate levels in the general clinical 
context while a reduction of serum lactate is still advocated as a target for treatment (Arnold 
et al 2009, Jones et al 2010). 
Among imaging techniques: chest X-ray, ECG, ultrasound scans of brain, heart and kidney 
are proposed.  
Minimally invasive monitoring like central vein access and arterial presuure monitoring, 
and non invasive tools like echocardiography are considered necessary in septic neonates.  
Hemodynamic variables including (perfusion pressure mean arterial pressure [MAP], minus 
central venous pressure [CVP]), and cardiac output (CO) should guide resuscitation 
treatment.  
The systemic circulation is represented by CO = (MAP - CVP)/SVR (systemic vascular 
resistance). This relationship is important for organ perfusion.  
Measurement of urine output and creatinine clearance can be also used as an indicator of 
adequate blood flow and perfusion pressure. Because blood pressure does not necessarily 
reflect CO, it is recommended that normal CO and/or SVC (superior vena cava) flow, 
measured by Doppler echocardiography, be a primary goal as well. (Carcillo et al 2002, 
Brieley et al 2009, Kluckow 2001, Kluckow et al 2000, Kluckow et al 2000 )  
Measurement of CO and O2 consumption were proposed as being of benefit in patients with 
persistent shock because a cardiac index (CI) between 3.3 and 6.0 L/min/m2 and O2 
consumption >200 mL/min/m2 are associated with improved survival (Pollack et al 1985). 
Because low CO is associated with increased O2 extraction, ScvO2 saturation can be used as 
an indirect indicator of whether CO is adequate to meet tissue metabolic demand. If tissue 
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oxygen delivery is adequate, then assuming a normal arterial oxygen saturation of 100%, 
mixed venous saturation is >70% .  
In VLBW infants, SVC blood flow measurement was reportedly useful in assessing the 
effectiveness of shock therapies and prognostic value because approximates blood flow 
from the brain. It has been observed that a value > 40 mL/kg/min is associated with 
improved neurologic outcome and survival. ScvO2 saturation can be used in low birth 
weight infants, but may be misleading in the presence of left to right shunting through the 
patent ductus arteriosus. (Kluckow 2001, Kluckow et al 2000, Kluckow et al 2000) 
Shock should be diagnosed before blood pressure decrease by clinical signs like 
hypothermia, hyperthermia, vascular alterations, tachycardia, bradycardia. Blood pressure 
should not be used as a marker of systemic blood flow in neonates because oxygen delivery 
to cells is dependent upon cardiac output and systemic blood flow than on blood pressure 
and a neonate may be hypotenisve but still have adequate oxygen delivery.  
E-selectin, a protein expressed by the endothelium after activation at sites of acute 
inflammation, taking part in the first step of the adhesion cascade, shows plasma levels higher 
in nonsurvivors than in survivors (P= .01) and in patients with hemodynamic dysfunction 
than in those without hemodynamic dysfunction (P _.001). (El Sayed Zaki et al 2009) 
6. Management 
In spite there are extensively studied multiple organ dysfunction scores and well-defined 
algorhythmic guidelines for treatment, there is a large amount of practice variability in 
neonatal septic shock.  
In the onset of septic shock an early and aggressive management of septic shock is needed 
because for each hour of delay the risk of death increases by 2 times. The immediate 
objective is to optimize the perfusion and delivery of oxygen and nutrients to tissues.  
According to the guidelines of the American College of Critical Care Medicine, 60 min is the 
average time needed to provide adequate circulatory support and block the development of 
shock. (Brierley et al 2009). Recognize decreased perfusion, cyanosis and respiratory distress 
syndrome (RDS), establishing an airway for adequate ventilation and oxygenation and 
obtaining rapid peripheral or central venous access or intraosseus access are the first steps in 
managing a newborn in shock (0-5 min) (7).  
It is important to rember that all babies with shock and hepatomegaly, cyanosis or pressure 
gap between upper and lower limbs should begin treatment with prostaglandin within 10 
min, until congenital heart disease is excluded (Carcillo et al 2002, Brieley et al 2009). 
A key element in the therapeutic management of septic shock is the early recognition of 
infection. One of the most important factors in progression from infection to septic shock is 
the use of inappropriate or delayed antibiotic therapy (Kumar et al 2006).  
6.1 Antibiotics 
After appropriate blood cultures, tests for biomarkers of sepsis, glucose and ionized calcium 
are made, the empirical antibiotic therapy must be established. 
A term neonate or a late pre-term infant ≤7 days of age with sepsis should be treated with 
ampicillin and gentamicin within 60 min. from the suspected diagnosis (Rao et al 2006). 
Many NICU use Cefotaxime, as a first-line agent, but neonates treated with ampicillin/ 
cefotaxime were more likely to die, and less likely to be discharged to home as compared to 
neonates treated with ampicillin/gentamicin (Clark et al 2006).  
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The empiric therapy for late onset sepsis (LOS) in term or late preterm infants admitted 
from the community after 7 days, is a combination of ampicillin and gentamicin too. In case 
of meningitis, cefotaxime is administered every 8 h instead of gentamicin. If there is history 
of prolonged hospitalization or the newborn infant has a central venous catheter (CVC) 
vancomycin is preferable to ampicillin. In this case, vancomycin and gentamicin/cefotaxime 
is preferable empiric coverage because provides additional coverage for S. aureus and 
CONS. Clindamycin is now recommended for susceptible MRSA isolates in term infants 
(Aneja et al 2011). 
Afetrwards, once the causative organism has been identified, antibiotics can be targeted 
only against that organism. As Herpes simplex virus Type I is one of the causes of 
intractable ‘shock’, anti-viral (acyclovir) medication, should be initiated, even in the absence 
of history of maternal infection with herpes virus, in infants who either does not respond. to 
standard therapy or has persistent signs and symptoms of infection with negative bacterial 
or fungal cultures or present in septic shock. (Haque 2007).  
Therapeutic plasma levels should be monitored because renal and hepatic dysfunction may 
lead to abnormal volumes and levels of distribution of drugs. The duration of antibiotic 
therapy is debatable. Serial measurements of CRP or preferably IL-6 or IL-8 are desiderable 
to minimize resistance, super-infection, and other complications from prolonged use of 
antibiotics. The decision to continue or stop antibiotic therapy must be based on clinical 
signs plus biomarkers of sepsis and not only on negative blood culture results, that are 
frequently negative. Intravascular access devices potential source of severe sepsis or septic 
shock should be promptly removed after establishing other vascular access.  
6.2 Mechanical ventilation 
Respiratory failure in severe sepsis and septic shock, due to low functional residual capacity 
may require elective intubation and ventilation to garantee oxygenation and tissue 
perfusion, trying to avoid hyperoxemia and over distention of alveoli, which is a potent 
inducer of IL-6 release.  
6.3 Hypoglycemia and hypocalcemia  
Correction of hypoglycemia and hypocalcemia should be done if needed. Hypoglicemia can 
cause neurological damage, if non corrected. Hyperglycemia, particularly cortisol-induced 
hyperglycemia, is immunosuppressive and prothrombotic. Being due to insulin resistance, 
which prevents glucose entering into the Krebs cycle, early institution of insulin therapy in 
hyperglycemic states ensures that glucose is delivered into the Krebs cycle, in particular to 
the cardiac muscles.  
There is no consensus as to what is the ideal blood glucose level, anyhow there is consensus 
that it should not be lower than 30 mg/dl. Similarly, there is no agreement as to what is the 
upper limit of blood sugar when insulin therapy should be initiated. In pediatric patients, a 
glucose level of 178 mg/dL or more was associated with a 2.59 increased risk of mortality 
(Branco et al 2005). Other researchers noted a similar outcome in extremely low-birth-
weight-infants who had glucose levels greater than 150 mg/dL. 
Solutions containing 10% dextrose as maintenance fluid are adequate to provide energy 
(glucose 4 to 8 mg/kg/minute).  
In septic shock strict glycemic controls are needed to avoid marked blood glucose levels 
changes, therefore it is advisable to prevent rapid fluctuation in blood glucose levels by 
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giving boluses or high concentration glucose infusion. Hyperglycemia peaks appear to be 
related with the disease severity.  
Since insulin hyperglycemia control in parenteral nutrition preterms has been responsible 
for hypoglycemic episodes effects,( Beardsall et al 2008) until better evidence is available, 
insulin is indicated in the newborn only when marked hyperglycemia is seen (> 180 
mg/dL), in refractory shock and unfavorable response newborns. (Vlasselaers et al 2009) 
Normalization of ionized calcium concentration should be the goal of calcium replacement, 
because hypocalcemia may be a reversible cause of cardiac disfunction.  
6.4 Bicarbonate therapy  
There is no evidence to support the use of bicarbonate therapy in the treatment of 
hypoperfusion induced acidemia, during sepsis. Bicarbonate solutions are very 
hyperosmolar even when diluted and if infused rapidly may increase the risk of ventricular 
hemorrhage in the newborn, particularly the preterm infants.  
6.5 Volume replacement 
Septic prematures microcirculation evaluation shows that changes are already detectable 24 
hours before the systemic sepsis parameters are apparent. (Weidlich et al 2009). The damage 
of vascular endothelium, caused by inflammatory mediators, results in vasodilation and 
fluid shifts into the interstitial space resulting in intravascular volume decrease. So neonates 
in shock often require volume replacement to maintain and/or restore adequate tissue 
perfusion. A significant reduction in mortality has been obtained if hemodynamic function 
is optimized in a few time (Rivers et al 2001). The underlying importance is the maintenance 
of preload and tissue perfusion.  
Volume expansion could be carried with crystalloids, colloid or blood products, if 
hemorrhage. Actually there is a lack of consensus in the literature regarding which product 
is most effective than the other. In clinical practice, crystalloids have been used more 
extensively because they are inexpensive and fluid retention and the incidence of adverse 
effects (eg, intraventricular hemorrhage and infection transmission) may be lower (Lynch et 
al 2008, Oca et al 2003). Normal saline and lactated ringers are 2 examples of crystalloid 
solutions used for volume expansion. Colloid solutions contain minerals and electrolytes. 
They increase oncotic pressure, do not easily cross semipermeable membranes, may remain 
in the intravascular space longer than crystalloids and allow to use small volumes with less 
incidence of pulmonary edema. The colloid most commonly used for volume expansion is 
5% albumin.  
In term infants or older preterm infants, aggressive volume expansion (push boluses of  
10–40 mL/kg up to 60mL/kg over 20 to 30 minutes should be considered (Carcillo et al 
2002). To prevent reperfusion injury it is preferable to increase the total volume and rate of 
fluid infusion rather than give repeated boluses of fluids.  
Those infants who after adequate fluid resuscitation do not self-diurese may need diuretics 
to prevent fluid overload. For very preterm neonates there is insufficient evidence to 
support early volume expansion because of a significant risk of intracranial hemorrhage 
associated with rapid volume expansion from fluctuations in cerebral perfusion and 
developing heart failure and/or pulmonary overcirculation from resultant left to right flow 
through a patent ductus arteriosus, specially in case of anemia. In the septic shock, when 
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6.6 Cardiovascular agents 
Inotropes are indicated when myocardial contractility remains compromised despite adequate 
volume replacement (Irazuzta et al 2007). They should be administered through a peripheral 
or intraosseous line before central access is available. A delay in administration of inotropes 
was associated with a 20-fold increased mortality risk (Kisson et al 2010). Medications in this 
group include dopamine, dobutamine, epinephrine, and norepinephrine. During neonatal 
sepsis can be established a hypodynamic state with vasoconstriction that may respond better 
to inotrope and vasodilator therapy than adults. Both dopamine and epinephrine were found 
to be efficacious in improving the mean arterial blood pressure but epinephrine was associated 
with more short-term adverse effects such as enhanced chronotropic response, hyperglycemia 
requiring insulin treatment, increased plasma lactate levels and inadequate gastric mucosa 
perfusion (Valverde et al 2006, Levy et al 2011). Recently, a randomized controlled trial 
showed that dobutamine increased systemic blood flow more effectively than dopamine 
(Osborn et al 2002). Anyhow Dopamine remains the first-line agent in neonates, and 
epinephrine may be used in dopamine-resistant septic shock (Carcillo et al 2002). Dopamine: is 
a natural precursor of both epinephrine and norepinephrine, stimulates the dopaminergic re-
ceptors β and α, in this order, with increasing dose. The initial dose of 5-10 mcg/kg/min is 
recommended and incremented by 2.5 mcg/kg/min steps every 10-15 minutes (Pellicer et al 
2009). The prematures may be resistant to its action due to deficient deposit of norepinephrine. 
A dose ≥ 10 mcg/kg/min dopamine may reduce TSH release, making difficult 
hypothyroidism diagnosis and producing relevant adverse effects such as tachycardia, 
arrhythmias, bradycardia, nausea and vomiting. If low cardiac output and high systemic 
vascular resistance persist, dobutamine and/or a type III phosphodiesterase inhibitor may be 
indicated. Dobutamine is frequently associated to dopamine in the newborn septic shock; 
Trough ǃ-adrenergic effects determines vasodilation, through ǂ-adrenergic myocardial recep-
tors stimulation, increases heart contractility and frequency. As reduces after-load, it is 
particularly useful for septic shock characterized by myocardial dysfunction and high 
peripheral resistance. In the premature, improves the systemic blood flow, however is not 
superior to dopamine for septic shock hypotension reversion. Dobutamine may reduce 
pulmonary vascular resistance, with additional benefit for PPH. Caution is advised when 
using dobutamine for LV flow obstruction patients. It may cause hypotension if the infant 
remains hypovolemic, and in higher doses causes tachyarrhythmia.( Dempsey et al 2009) . In 
the term or near-to-term newborn, once assured previous losses replacement and started 
volume resuscitation, ǃ-adrenergic (inotropic) dose dopamine is indicated between 5-9 
mcg/kg/min associated with dobutamine 2.5-10 mcg/kg/min, already during the first man-
agement hour (Brierley et al 2009, Pellicer et al 2009). If the patient does not adequately 
respond to these interventions, then epinephrine (0.05– 0.3 µg/kg/min) can be infused. For 
extreme premature transition period shock, the best starting vasoactive drugs schedule was 
not yet established.(Noori et al 2009) It is very important to have service procedures 
standardized to control for the results. Dopamine use is safe in these patients. A combination 
of dopamine at low dosage and dobutamine is initially recommended. Epinephrine At a low 
dose < 0.03 mg/kg/min acts as a potent inotrope (ǃ1), chronotrope (ǂ1), and both systemic 
and pulmonary vasodilatator (ǃ2). At higher doses, has systemic and pulmonary circulation 
vasopressor effect (ǂ-adrenergic). The use of Norepinephrine is limited in neonatal shock. It is 
indicated for “warm” shock (doses 0.05 to 0.5 mcg/kg/min), an uncommon condition in the 
newborn. Tourneux et al.obtained improved blood pressure and PPH-related hemodynamic 
values and positive effects on the heart and cerebral flow (Tourneux et al 2008).  
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6.7 Corticosteroids  
Corticosteroids are often used to treat shock when volume expansion and inotropes are 
ineffective to raise blood pressure. They may act by improving the vessel wall sensitivity to 
circulating cathecolamines or to exogenous vasoactive drugs, inhibiting the nitric oxide 
synthase enzyme expression, or suppressing immune responses. Additionally, septic 
newborns may develop relative adrenal insufficiency, manifested by low stress cortisol 
levels.(Fernandez et al 2008) Despite this, the use of corticosteroids remains relatively 
untested. A recent large cohort study of steroid administration to children and infants with 
severe sepsis showed no improvement in outcome and an increase in mortality in a subset 
of patients (Markovitz et al 2005).  
Hydrocotisone and dexamethasone are the most used steroids. There are no specific 
recommendations for neonates regarding the use of dexametasone, conversely 
Hydrocotison is life saving and should be reserved for refractory shock patients, or in 
services missing inodilators (milrinone), in epinephrine-resistant shock, when adrenal 
insufficiency is suspected (Vincent 2008). The dose of hydrocortisone ranged from the 
“stress-dose” used in adrenal insufficiency of 1–2 mg/kg to the empirical shock dose of 50 
mg/kg. (Parker et al 2004). Higher mean arterial blood pressures and less vasopressor 
support and volume expanders use were observed in neonates treated with low-dose 
hydrocortisone (NG et al 2006).  
6.8 Nutrition 
Severe illness causes a catabolic process, increases an infant’s metabolic requirements, 
specially in preterm infants owing to poor muscle mass and energy reserves. Appropriate 
quantities of energy, minerals, and vitamins can be provided rather by enteral feedings to 
reduce bacterial translocation from the gut mucosa into the circulation and preserve gut 
mucosal function. 
7. Adjuntive treatments 
7.1 Nitric oxide (iNO) 
Infants with sepsis and persistent pulmonary hypertension (PPHN) may require iNO to 
reduce pulmonary vascular resistance and off-load the right ventricle (Roberts et al 
1997). The dose of NO with the best results is generally 20 ppm.  
7.2 Triiodothyronine 
Is an effective inotrope in newborns in case of thyroid insufficiency (Carcillo et al 2002, 
Carcillo et al 2009).  
7.3 Phosphodiesterase inhibitors 
Phosphodiesterase inhibitors are indicated if cardiac output does not improve and high 
systemic vascular resistance persists. 
7.4 Milrinone 
Milrinone is an inodilator (inotrope/vasodilator) that exerting the selective phosphodiesterase 
type III inhibition, improves myocardial contractility and relaxation by effects on calcium 
influx, efflux, and myofilament calcium binding. In the vasculature relaxes arterial and venous 
smooth muscle. These properties have led to increased use of Milrinone in shocked newborns 
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with high peripheral vascular resistance (“cold” shock), ventricular dysfunction and normal 
pressure, specially with PPH, epinephrine-resistant shock with the aim to increase cardiac 
contractility and cardiac output (Paradisis et al 2006, Paradisis et al 2007). Milrinone due to its 
sistemic and pulmonary vasodilatator effects may need volume expansion or inotropic 
support during the therapy. The recommended dose is 0.75 mcg/kg/min for 3 hours, followed 
by 0.2 mcg/kg/min. Limited data are available about the use of milrinone in preterm infants. 
Milrinone failed to show significant effects in extreme low systemic flow prematures within 
their first 24 hours of life. In these subjects it should be used under hemodynamic control. It is 
also important to consider that this subjects have a glomerular filtration rate riduced by half 
compared to term infants in the first 2 weeks of life and that the velocity of improvement over 
the first several weeks of life is riduced. (Paradisis et al 2009). These differences among varying 
gestational age newborns make that dosing should be often renally adjusted. Lindsay et al 
used a loading doses of 75 g/kg and a start infusion rates of 0.75 to 1.0 g/kg/min for patients 
with normal renal function. The authors recommanded for every increase of 0.25 g/kg/min, a 
25 g/kg bolus dose be given. Because the median half-life is 1.47 hours, immediate 
hemodynamic effects may not be seen unless appropriate loading doses and infusion 
adjustments are made. (Lindasy et al 1998) 
7.5 Arginine-vasopressin (AVP)  
AVP and TP are 2 forms of vasopressin indicated for rescue therapy in neonates and 
pediatric patients in case of catecholamine-refractory shock, able to determine an increase 
in arterial pressure within 1 hour after administration. The meta-analysis conducted by 
Meyer et al. did not demonstrate a clear advantage of one drug over the other (Vincent.et 
al 2006, Meyer et al 2008).  
Endogenous AVP, released in response to hypovolemia and hypotension, shows a biphasic 
response in septic shock, with initial high levels followed by inappropriately low levels, that 
more likely occurs after 36 hours from the onset of shock in approximately one third of late 
septic shock patients.(Sharshar et al 2008) This justifies exogenous administration to correct 
hypotension in vasodilatory shock in children and also in extremely-low-birth weight infants.  
The best dosages of vasopressin remain controversial. Dosages of 0.067 IU/min seem to be 
more effective to reverse cardiovascular failure in vasodilatory shock requiring high 
norepinephrine dosages than 0.033 IU/min. (Luckner et al 2007) 
Low-dose vasopressin (0.04 IU/min) infusion has been shown to be effective in reversing 
catecholamine-resistant hypotension in adult septic shock patients. (Klinzing et al 2007). 
However, one should keep in mind that the pressor activity of vasopressin in the absence of 
shock, is minimal.  
A study suggested that vasopressin is more efficient to increase urine output than 
norepinephrine. (Patel et al 2002). However, use of vasopressin instead of norepinephrine 
cannot be recommended.  
7.6 Terlipressin (TP) 
A synthetic AVP analogue with prolonged action and a higher affinity for vascular receptors 
than vasopressin. Recently resulted effective in rescue treatment of refractory vasodilatory 
septic shock, although few data are available. Its use has been promoted because vasopressin 
is not available in most European countries. It is considered as a last resort when septic 
patients remain hypotensive despite fluid resuscitation and high doses of cathecolamine.  
As a prodrug, TP is continuously converted by endopeptidases to vasoactive lysine-
vasopressin with a peak level approximately 10 minutes after intravenous administration. 
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Accordingly, despite low plasma levels it has a prolonged action. In fact, half-life is 6 h for 
TP versus 6 min for VP and duration of action is 2–10 h versus 30–60 min, respectively (Kam 
et al 2004). This allows TP intermittent administration without hypotension rebound at drug 
withdrawal. An intermittent intravenous dosing schedule of approximately every 4 to 6 
hours would be appropriate (Pesaturo et al 2006). Matok et al administered TP in an 8-day-
old neonate with refractory septic shock to dopamine, milrinone and adrenaline, as rescue 
therapy (0.07 mg/kg twice a day). Rapid BP improvement and tissue perfusion without side 
effects, followed (Matok et al 2004). Similarly Filippi et al. used TP because of refractory 
hypotension in a shocked but not septic neonate, at dose of (0.02 mg/kg every 4 h) with a 
maximum duration of therapy of 60h. BP dramatically increased 30 min after the first bolus 
and diuresis was promptly re-established, indicating improvement of tissue perfusion. MAP 
rapidly increased so that adrenaline and norepinephrine, dopamine and dobutamine were 
reduced and stopped so TP was administered as the only vasopressor. No rebound 
hypotension occurred (Filippi et al 2008).  
No evidence exists at present on the appropriate timing of TP initiation. Some data suggest 
that in infants TP should be administered when norepinephrine need is 0.5-2.5  µg/kg/min, 
probably a precocious administration may be beneficial in order to avoid episodes of severe 
hypotension (Filippi et al 2008, Zeballos et al 2006, Rodríguez-Núñez et al 2010). In adult 
preliminary clinical data on ultra low dose terlipressin infusion as first line agent, suggest 
that ‘‘the earlier may be the better’’ (Morelli et al 2008). However, the level of evidence 
based on the data available in the literature is very low. 
Low-dose continuous infusion has also been described. (Leone et al 2008). Nunez et al 
obtained an increase of median MAP 30 minutes after administration and a norepinephrine 
infusion reduction through continuous terlipressin infusion in pediatric refractory septic 
shock. After a loading dose of (20 μg/kg) was administered a continuous infusion at a rate 
of 4–20 μg/kg/h (Rodrı´guez-Nu´n˜ez et al 2008).  
Terlipressin experimental studies showed a protective effect from capillary leakage, less 
rebound hypotension during weaning (Westphal Westphal et al 2009, Rehberg et al 2009, 
Morelli et al 2009).  
Ischaemic adverse effects secondary to local vasoconstriction, as in the skin and gut were 
reported in children above all if TP was administered as intermittent bolus. A fact that 
promoted in adults the TERLIVAP study based on TP continuous infusion and significantly 
lower dose (1.3 μg/kg/h) to limit this adverse effects (Morelli et al 2009).  
7.7 Levosimendan  
Levosimendan is an extensively investigated inodilator showing cardioprotective and 
antiinflammatory effects. Levosimendan is a calcium-sensitizing agent acting by binding to 
myocardial troponin C in a calcium-dependant manner, causing a configuration change in 
tropomyosin. This exposes actin and myosin elements, allowing more efficient contraction. 
In peripheral vascular beds, levosimendan opens adenosine triphosphate–sensitive vascular 
potassium channels, causing hyperpolarization and vascular relaxation. This effect reduces 
cardiac afterload and promotes coronary vasodilation. In adults has been demonstrated 
benefits in low cardiac output states (Moiseyev et al 2002, Slawsky et al 2000).  
Levosimendan potential utility is due to a number of reasons; it can be used with 
conventional inotropic agents, has a simple dosing regimen, and does not worsen the 
diastolic dysfunction often present in structural heart disease. Levosimendan has received 
little attention in the pediatric field other than 2 case reports. In both case with clinical 
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improvement (Luther et al 2004, Braun et al 2004). Egan et al (2006) in their experience with 
19 cardiac surgical infants and children documented the improvement of myocardial 
contractility and perfusion, particularly when used early in the evolution of the low cardiac 
output syndrome, without increasing myocardial oxygen consumption and negative events. 
Recently Hasslacher et al (2011) showed that levosimendan reduces oxidative burst activity of 
PMN both in vitro and in patients with acute heart failure or septic shock with septic 
myocardial depression. This may contribute to the anticipated cardioprotective effects of the 
drug. It has a half life of 1 hour and a duration of action of 4 days. The recommended dose is 6-
12 mcg over 60 min, followed by continuous infusion at 0.05 to 1 mcg / kg / min for 24 hours.  
7.8 Granulocyte and granulocyte-macrophage colony stimulating factors  
(G-CSF, GM-CSF)  
The use of G-CSF, GM-CSF has been shown to increase the number of circulating white cells 
but don’t reduce mortality from neonatal sepsis or septic shock (Carr et al 2003).  
7.9 Pentoxifylline  
Pentoxifylline is a carbonic anhydrase inhibitor that has been shown to improve white cell 
function. In one randomized controlled trial in prematures infants, was shown to 
significantly reduce the development of multiorgan failure, mortality and coagulopathy 
with improvement of blood pressure (Lauterbach et al 1999). This is currently a promising 
option for refractory shock dosed at 5 mg/kg/hour for 6 hours for next 5 days. 
7.10 Intravenous immunoglobulin (IVIG)  
Polyclonal and IgM-enriched IVIG have been shown to reduce mortality from sepsis in 
newborn infants. The activity of Tumour necrosis factor (TNF), a major pro-inflammatory 
cytokine, can be blocked by various antagonists. In a search was designed a single-domain 
monoclonal antibody (VHH), which recognizes TNF biologically active in vivo. Therefore, 
therapeutic application of TNF-VHH-ELP fusion protein was tested in humanized TNF mice 
and was shown to be effective in preventing death caused by septic shock. 
Immunomodulator agents have shown frustrating results in newborn septic shock 
management. (Conrad et al 2011) 
7.11 Protein C (PC) 
The strong activation of coagulation occurring during sepsis may cause the depletion of PC, 
a vitamin K dependent natural anticoagulant, which exerts a crucial role in the modulation 
of  coagulation, fibrinolysis, and inflammation. Low PC plasma activity correlates with 
adverse outcomes, such as multiple organ failure and mortality. It has been considered a 
useful predictor of organ failure in severe sepsis and an important factor of high diagnostic 
and negative prognostic significance. (Shaw et al 2011, Lauterbach et al 2006, Venkataseshan 
et al 2007).  
Recently in an animal newborn model, was demonstrated impairment of intestinal 
microcirculation early after induction of endotoxic shock, and its prevention through to 
continuous infusion of 24 μg/kg/h activated PC (aPC). This underlines that the use of PC 
results in an improvement of sepsis-induced microcirculatory dysfunction. (Fischer et al 
2009) and underlines the warrants of its supplementation. Whereas several studies, in adults 
and children, has shown some significant reduction in septic shock mortality thanks to aPC 
supplementation, a large clinical trial was stopped early, due the finding of an increased 
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incidence of intracranial bleeding in children younger than 60 days (Nadel et al 2007). In 
addition, the efficacy of aPC may also be different in neonates due to underlying 
developmental differences in the coagulation pathway. The anticoagulant effect of aPC has 
been shown to be decreased in neonatal cord plasma, which is due, in part, to the lower 
levels of tissue factor pathway inhibitor, antithrombin and protein S in neonatal versus 
adult plasma (Bernard et al 2001, Cvirn et al 2005). In contrast, non-activated plasma-
derived human protein concentrate (PCConc) has been successfully used in paediatric, 
neonatal and adult patients at high-risk of haemorrhage, especially in those suffering from 
meningococcal septic Shock (de Kleijn et al 2003). PCConc has been successfully used in 
term neonates and preterms at high-risk of haemorrhage with sepsis-induced coagulopathy 
(Fischer et al 2009, Decembrino et al 2010). Supplementation was followed by micro- and 
macrocirculatory, haemodinamic parameters and coagulation, improvement, increased 
levels of PC activity. PCConc was given intravenously as bolus administration of 200 IU ⁄ kg 
/day or 100 IU ⁄ kg/day followed by a daily bolus administration of 50 IU ⁄ kg every 6 h for 
72 h. No adverse events were observed. 
When enough prothromotic factors are consumed, spontaneous bleeding occurs. It is 
important, therefore, to determine early whether the infant is in a prothrombotic or 
fibrinolytic phase. Appropriate coagulation studies should be undertaken. If the baby has a 
prolonged prothrombin time/partial thromboplastin time and low fibrinogen then it is 
likely to be DIC. If, however, fibrinogen levels are normal or high then it is likely to be 
thrombotic thrombocytopenic purpura. Even if routine use of fresh frozen plasma to correct 
laboratory clotting abnormalities is not recommended, some professional bodies find it 
useful. The transfusion of platelets is recommended when platelets are between 5000 and 
30,000 × 109/l. 
8. Septic shock in preterms 
The therapeutic approach of very low birth weight is affected by specific hemodynamic 
response and multiple factors. The echocardiographic evidence of a reduction of the right 
and left ventricular function, leads to the use of volume expanders and inotropic to improve 
cardiac output, contractility and blood pressure. Parathyroid, adrenal and thyroid hormone 
deficit may require therapy with thyroid hormones, calcium or hydrocortisone. Immaturity 
of thermogenic mechanisms needs special heating measures.  
During the first three days of life the extremely very low birth weight (BW < 1,000 g) 
frequently with maternal chorioamnionitis history, metabolic acidosis and altered perfusion 
in the first 24 hours of life, often present progressive respiratory worsening, tachycardia, 
silent ductus arteriousus. In this case, a rapid infusion of fluid above 30 mL/kg during the 
first 48 hours of life is responsible for left-right shunt, congestive heart failure and 
ventricular overload and increased mortality (Ewer et al 2003, Hamrick et al 2010) The 
failure to close the patent ductus is associated with increased mortality, intraventricular 
hemorrhage, and poor neurodevelopmental outcome.(Noori et al 2009). Ultrasonography 
techniques to estimate superior vena cava flow and heart output are effective to replace 
MBP as an evaluation tool, although not widely available. 
The optimal shock oxygenation for extreme prematures it is not yet determined. If under too 
restricted saturation control (between 83% - 89%), they have increased patent ductus 
arteriosus incidence. (Noori et al 2009) On the other hand, the harmful hyperoxia effects on 
ischemic tissues reperfusion are also feared. In extreme prematures, saturation > 94% should 
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be avoided. PaO2 should not be kept in supra-systemic levels. (Hamrick et al 2010, 
Weindling et al 2007) 
9. Conclusion 
Despite major improvements in the management of severe sepsis, neonates can develop 
septic shock, a critical condition associated with high morbidity and mortality. For these 
reasons neonatal septic shock requires emergency treatment with antibiotics, appropriate 
fluid resuscitation and vasoactive drugs. Knowledge of risk factors will help to identify 
those neonates at greatest risk for development of septic shock. In the future genomic and 
proteomic approaches may be helpful in early diagnosis. Although at present antimicrobial 
therapy and supportive care remain the foundation of treatment, it is desirable that future 
agents may improve outcomes, specially for particularly vulnerable premature neonates. It 
is estimated that intra-uterine infection, a risk factor for developing severe infection, is 
present in up to 35% of preterm deliveries [2]. 
 
SIRS: presence of at least 2 of the following 4 criteria, 1 of which must be abnormal 
temperature or leukocyte count: 
• Core temperature of >38.5°C or <36°C 
• Tachycardia, defined as a mean heart rate >2SD more than normal for age in the 
absence of external stimulus, chronic drugs, or painful stimuli; or otherwise 
unexplained persistent increase in a 0.5- to 4-h time period OR for children <1 y old: 
bradycardia, defined as a mean heart rate <10th percentile for age in the absence of 
external vagal stimulus, b-blocker drugs, or congenital heart disease; or otherwise 
unexplained persistent depression in a 0.5-h time period 
• Mean respiratory rate >2SD more than normal for age or mechanical ventilation for 
an acute process not related to underlying neuromuscular disease or the receipt of 
general anesthesia 
• Leukocyte count increased or decreased for age (not secondary to chemotherapy-
induced leukopenia) or >10% immature neutrophils 
Infection: a suspected or proven (by positive culture, tissue stain, or polymerase chain 
reaction test) infection caused by any pathogen OR a clinical syndrome associated with a 
high probability of infection. Evidence of infection includes positive findings on clinical 
examination, imaging, or laboratory tests (eg, white blood cells in a normally sterile body 
fluid, perforated viscus, chest radiograph consistent with pneumonia, petechial or 
purpuric rash, or purpura fulminans). 
Sepsis: SIRS in the presence of or as a result of suspected or proven infection. 
Severe sepsis: sepsis plus 1 of the following: cardiovascular organ dysfunction OR ARDS 
OR 2 or more other organ dysfunctions. 
Septic shock: sepsis and cardiovascular organ dysfunction. 
From Goldstein B, Giroir B, Randolph A. International pediatric sepsis consensus conference: 
definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 2005;6(1):2–8. 
Fleer A, Krediet TG. Innate immunity: toll-like receptors and some more. A brief history, basic 
organization and relevance for the human newborn. Neonatology. 2007;92(3):145-57. 
Table 1. Definition of systemic inflammatory response syndrome (SIRS), infection, sepsis, 
severe sepsis, septic shock  
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Despite administration of isotonic intravenous fluid bolus >40 mL/kg in 1h 
• Decrease in BP (hypotension) <5th percentile for age or systolic BP >2SD less than 
normal for age 
OR 
• Need for vasoactive drug to maintain BP in normal range (dopamine >5 mg/kg/min 
or dobutamine, epinephrine, or norepinephrine at any dose) 
OR 
• Two of the following: 
Unexplained metabolic acidosis: base deficit >5.0 mEq/L 
Increased arterial lactate >2 times upper limit of normal 
Oliguria: urine output <0.5 mL/kg/h 
Prolonged capillary refill >5 s 
Core to peripheral temperature gap >3°C 
Pulmonary: 
• PaO2/FIO2 <300 in absence of cyanotic heart disease or preexisting lung disease 
OR 
• PaCO2 >65 torr or 20 mm Hg more than baseline PaCO2 
OR 
• Proven need for >50% FIO2 to maintain saturation >92% 
OR 
• Need for nonelective invasive or noninvasive mechanical ventilation 
Neurologic: 
• Glasgow Coma Score >11 
OR 
• Acute change in mental status with a decrease in Glasgow Coma Score >3 points 
from abnormal baseline 
Hematologic: 
• Platelet count <80,000/mm3 or a decline of 50% in platelet count from highest value 
recorded in the past 3 days (for chronic hematology/oncology patients) 
OR 
• International normalized ratio >2 
Renal: 
• Serum creatinine >2 times upper limit of normal for age or 2-fold increase in baseline 
creatinine 
Hepatic: 
• Total bilirubin >4 mg/dL (not applicable for newborn) 
OR 
• ALT 2 times upper limit of normal for age 
From Goldstein B, Giroir B, Randolph A. International pediatric sepsis consensus conference: 
definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 2005;6(1):2–8. 
 
Table 2. Organ disfunction criteria  
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• Infant 72 hours or less in age. 
• Tachypnea (Respiratory rate > 60 bpm) plus either grunting/retraction or 
desaturations. 
• Temperature instability ( <36°C or > 37-9 °C) 
• Capillary refill time > 3 seconds 
• WBC count ( ‹ 4000 × 109/L or 8 34,000 × 109/l) 
• CRP > 10 mg/dl 
• IL-6 or IL-8 > 70 pg/ml 
• 16S rRNA gene PCR: Positive. 
• WBC: white blood cell; CRP: C-reactive protein; IL: interlukin; rRNA: recombinant 
RNA; PCR: polymerase chain reaction. 
From Haque KN (2005) Definitions of blood stream infection in the newborn. Pediatr Crit Care Med 6 
(Suppl):545–549 
Table 3. Two or more of the following are required to diagnose the fetal inflammatory 
response syndrome (FIRS) 
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